Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences
TUCSON, Ariz. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C.
Toggle Summary HTG Introduces Oncology Applications and Expands Analytics Capabilities with Release of New Software Update
TUCSON, Ariz. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commercial release and immediate availability of HTG EdgeSeq Reveal version 3.0, adding additional
Toggle Summary HTG Molecular Provides Update on Patent Infringement Claims Against BioSpyder
TUCSON, Ariz. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today provided an update regarding its patent infringement claims against BioSpyder Technologies, Inc (BioSpyder).
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2020 Results
Call scheduled for today, August 11, at 4:30pm ET TUCSON, Ariz. , Aug. 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2020
Toggle Summary HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN
TUCSON, Ariz. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement (Master Agreement) with QIAGEN Manchester

Stock Chart

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities